Showing 2 of 10 years of data. Sign up free for 3 years, or upgrade for full access.
View PlansCash Conversion
1.02x
SUNPHARMA's operating cash flow exceeded net income in FY 2025, indicating earnings are backed by actual cash generation.
Free Cash Flow
₹119.44B
SUNPHARMA's free cash flow was ₹119.44B in FY 2025, up 20.2% from FY 2024.
Dividend Coverage
3.3x
SUNPHARMA's free cash flow covered dividends 3.3x in FY 2025, leaving room for reinvestment or debt reduction.
CapEx Intensity
15.1%
Capital expenditure was 15.1% of operating cash flow in FY 2025 for SUNPHARMA, indicating a capital-light business.
Hover the chart icon for YoY change.
| Item | Chart | 2024 | 2025 |
|---|---|---|---|
| Net Income | 110.88B | 137.52B | |
| Cash flow Operating Activities | 121.35B | 140.72B | |
| Investments in PPE | -22.02B | -21.29B | |
| Cash flow Investing Activities | -6.90B | -53.06B | |
| Dividend Paid | -29.01B | -36.14B | |
| Cash flow Financing Activities | -67.10B | -79.06B | |
| Cash at beginning of period | 46.24B | 92.86B | |
| Cash at end of period | 92.86B | 102.69B | |
| Free Cash Flow | 99.33B | 119.44B |
Values are shown in millions (M) and billions (B). All amounts are in Indian Rupees (₹).
Data from audited consolidated filings. For educational purposes only — not investment advice. Last update: Mar-2025